Search Result

Isoforms Recommended:	Phospholipase C

Results for "

plc-

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (3) Angiotensin Receptor (2) Antibiotic (3) Apoptosis (7) Arrestin (2) Aurora Kinase (1) Bacterial (4) Biochemical Assay Reagents (6) Btk (3) Calcium Channel (4) Cannabinoid Receptor (1) Caspase (1) CCR (1) CXCR (1) Dopamine Receptor (2) Drug Derivative (1) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (1) Endothelin Receptor (1) Environmental Pollutants (1) ERK (3) Estrogen Receptor/ERR (1) Ferroptosis (1) FGFR (1) Histone Demethylase (1) HIV (1) IFNAR (1) Interleukin Related (1) Itk (3) Lactate Dehydrogenase (1) Lipoxygenase (1) mGluR (2) Mitochondrial Metabolism (1) Mitosis (2) mTOR (2) NF-κB (1) Nuclear Factor of activated T Cells (NFAT) (1) Opioid Receptor (1) p38 MAPK (2) PARP (1) PD-1/PD-L1 (1) PDGFR (2) PERK (1) Phospholipase (23) PI3K (1) PROTACs (4) RANKL/RANK (1) Reference Standards (3) Reverse Transcriptase (2) Small Interfering RNA (siRNA) (2) Syk (1) Trk Receptor (3) TSH Receptor (1) VEGFR (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (4) Endocrinology (1) Infection (9) Inflammation/Immunology (9) Metabolic Disease (4) Neurological Disease (13)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0470

Neomycin sulfate Maximum Cited Publications 68 Publications Verification	Environmental Pollutants Antibiotic Phospholipase Bacterial	Infection Metabolic Disease Cancer
Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin sulfate inhibits IP3-mediated Ca ²⁺ release, MgATP-dependent Ca ²⁺ uptake, and electrical excitation-evoked skeletal muscle Ca ²⁺ transients. Neomycin sulfate depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin sulfate can be used for the research of cancer .

HY-13419

U-73122 Maximum Cited Publications 98 Publications Verification	Phospholipase Lipoxygenase Ferroptosis	Inflammation/Immunology
U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC₅₀of 1-2.1 µM for PLC.

HY-70072

D609 5+ Cited Publications	Phospholipase	Infection Inflammation/Immunology Cancer
D609, an antitumoural xanthate, is a specific and competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor with a K_i of 6.4 μM. D609 is an antioxidative protector and has antiviral and anti-inflammatory activity .

HY-19619

m-3M3FBS 5+ Cited Publications	Phospholipase Apoptosis	Cancer
m-3M3FBS is a potent phospholipase C (PLC) activator. m-3M3FBS stimulates superoxide generation in human neutrophils, upregulates intracellular calcium concentration, and stimulates inositol phosphate generation in various cell lines. m-3M3FBS induces monocytic leukemia cell apoptosis .

HY-12598A

DHPG 4 Publications Verification (RS)-3,5-DHPG	mGluR	Neurological Disease
DHPG is the agonist for mGluR 1/5 (EC₅₀ for mGluR 1 is 60 nM) that activates the phospholipase C (PLC) pathway, and leads ultimately to the activation of protein kinase C (PKC) .

HY-N9480

Vinaxanthone 3 Publications Verification SM-345431	Phospholipase Bacterial	Infection Cancer
Vinaxanthone (SM-345431) is a potent and selective semaphorin3A, phospholipase C (PLC) and FabI inhibitor, with IC₅₀s of 0.1-0.2 μM and 0.9 mM for semaphorin3A and FabI. Vinaxanthone inhibits the substrate (t-o-NAC thioester) and the cofactor (NADPH) with K_is of 3.1 μM and 1.0 μM, respectively. Vinaxanthone can be used to handle infections caused by multidrug-resistant pathogens .

HY-178018

D574-0246 iOXCT1	Mitochondrial Metabolism	Cancer
D574-0246 is a dual-activity inhibitor of OXCT1, inhibiting both the ketolytic and succinyltransferase activities of OXCT1. D574-0246 reduces substrate-specific (LACTB K284) and global protein succinylation and decreases OXCT1 ketolytic activity in HepG2 cells. D574-0246 inhibits the viability of HCC cells (IC₅₀: 16.49 μM in PLC cells, 6.656 μM in HepG2 cells). D574-0246 exerts anti-tumor efficacy in nude mice bearing OXCT1-overexpressing HepG2 xenograft tumors. D574-0246 can be used for the study of hepatocellular carcinoma (HCC) .

HY-108630

U-73343 5+ Cited Publications	Phospholipase	Others
U-73343, works as a protonophore, is an inactive analog of U-73122 and can be used as a negative control. U-73343 dose-dependently inhibits acid secretion irrespective of the stimulant. U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC₅₀ of 1-2.1 μM for PLC .

HY-P2141

TRV-120027 3 Publications Verification TRV027	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-137465

CG428	PROTACs Trk Receptor	Cancer
CG428 is a potent and selective CRBN-dependent tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 TPM3-TRKA fusion protein in KM12 colorectal carcinoma cells (DC₅₀ = 0.36 nM) and inhibits downstream PLCγ1 phosphorylation (IC₅₀ = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). CG428 can be used for the research of colorectal carcinoma .

HY-150520

Neomycin	Antibiotic Phospholipase	Infection Cancer
Neomycin, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin is a known phospholipase C (PLC) inhibitor. Neomycin potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin inhibits IP3-mediated Ca ²⁺ release, MgATP-dependent Ca ²⁺ uptake, and electrical excitation-evoked skeletal muscle Ca ²⁺ transients. Neomycin depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin can be used for the research of cancer .

HY-111208

CCT129957	Phospholipase	Cancer
CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC₅₀ of ~3 μM and a GC₅₀ of 15 μM. CCT129957 inhibits Ca ²⁺ release in squamous carcinoma cells at ~15 μM .

HY-P991413

ZEB85	Trk Receptor ERK Akt p38 MAPK	Neurological Disease Inflammation/Immunology
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .

HY-N0084

Betulinaldehyde 5 Publications Verification Betulinic aldehyde; Betunal	Bacterial	Infection Cardiovascular Disease Cancer
Betulinaldehyde (Betunal) Has anti-cancer and anti-staphylococcus aureus activity. Betulinaldehyde Suppressible Akt, MAPK sum STAT3 Signal path, increase self-transfer, Suppression A549 Cellular vitality, increase and transfer. Betulinaldehyde suppresses PLCγ1/Ca ²⁺/MMP9 signal pathway, has a key effect on vascular plasticity, and is available for cardiovascular disease (CVD) research.

HY-148123

Glycerophospholipids, cephalins	Biochemical Assay Reagents	Neurological Disease
Glycerophospholipids and cephalins are a class of phospholipid compounds and important components of neural membranes. Glycerophospholipids and cephalins are hydrolysis substrates of phospholipase (such as PLA2, *PLC, and PLD*). After complete hydrolysis, they produce 1 mol of glycerol, phosphate, ethanolamine, and 2 mol of fatty acids, respectively. Glycerophospholipids and cephalins can maintain membrane structure, fluidity, and ion permeability, and serve as precursors of second messengers such as arachidonic acid and diacylglycerol. Glycerophospholipids and cephalins can regulate signal transduction, cell apoptosis, and membrane transport, and are used in the study of neurodegenerative diseases (such as Alzheimer's disease) .

HY-12825

BHPI	Estrogen Receptor/ERR Phospholipase	Cancer
BHPI is a nuclear receptor ERα inhibitor. BHPI activates PLCγ and UPR. BHPI has antitumor activity against breast, endometrial, and ovarian cancers .

HY-123070

ONO-RS-082	Phospholipase	Inflammation/Immunology
ONO-RS-082 is an inhibitor of phospholipase A (PLA) . ONO-RS-082 inhibits PLA2 with the IC₅₀ of 1.0 μM, but does not inhibit PLC even at 100 μM .

HY-116874

SKF 83822 1 Publications Verification	Dopamine Receptor	Neurological Disease
SKF 83822 is an atypical agonist of dopamine D1 receptor. SKF 83822 activates adenylyl cyclase (AC), but not phospholipase C (PLC). SKF 83822 is also proved to stimulate AC via cAMP production. SKF 83822 can be used for research of schizophrenia .

HY-108608

o-3M3FBS	Calcium Channel	Others
o-3M3FBS is the negative control of m-3M3FBS. o-3M3FBS inhibits inward and outward currents via mechanisms independent of PLC acting in an antagonistic manner. In contrast, o-3M3FBS also causes an increase in [Ca ²⁺]_i in an agonistic manner .

HY-163985

PROTAC FGFR2 degrader 1	PROTACs FGFR Apoptosis	Cancer
PROTAC FGFR2 degrader 1 (compound N5) is a PROTAC that effectively targets FGFR2 with DC₅₀ of 6.46 nM, the FGFR2 IC₅₀ is 0.08 nM. PROTAC FGFR2 degrader 1 has anti-proliferative activity and highly selective, induces G0/G1 arrest of KATOIII and SNU16 cell cycle and inhibits apoptosis by reducing the activation of p-ERK and p-PLCγ, the downstream proteins of FGFR2. PROTAC FGFR2 degrader 1 inhibits gastric cancer cells remained above 50% at a concentration of 0.17 nM. PROTAC FGFR2 degrader 1 potently inhibits the growth of SNU16 xenograft tumors in mouse model (Structure Note: Pink, FGFR2 activator: HY-18708; Blue, E3 ligase ligand: HY--10984; Black, linker: HY-163989; E3 ligase ligand + linker：HY-163986) .

HY-135799

WH-15	Phospholipase	Neurological Disease Cancer
WH-15 is a fluorogenic *PLC* reporter with K_m value of 49; 30, 86.1 µM for PLC-γ1, PLC-δ1, PLC-β2, respectively. WH-15 can be cleaved in a cascade reaction to generate fluorescent 6-aminoquinoline. WH-15 can be used to respond to imaging PLC activity in live cells (Ex/Em = ~344/530 nm) .

HY-100045

p-Nitrophenyl phosphorylcholine 4-Nitrophenylphosphorylcholine; 4-Nitrophenylphosphorylcholine; O-(4-Nitrophenylphosphoryl)choline	Endogenous Metabolite	Metabolic Disease
p-Nitrophenyl phosphorylcholine (4-Nitrophenylphosphorylcholine) is a chromogenic substrate that is used to measure phospholipase C (PLC) activity. Hydrolysis of p-nitrophenylphosphorylcholine by PLC results in the liberation of p-nitrophenol, which can be measured at 405 nm at pH 7.2-7.5.

HY-N1773

5,7,3'-Tri-O-methyl (-)-epicatechin	Others	Cancer
5,7,3' -tri-O-Methyl (-)-epicatechin (Compound 13) is a phospholipase Cγ1 (PLCγ1) inhibitor. 5,7,3' -tri-o-methyl (-)-epicatechin has a methylene dioxy benzene ring and can express inhibitory activity against PLCγ1. 5,7,3' -tri-O-Methyl (-)-epicatechin can be used in the study of chemotherapy and chemopexic agents for cancer .

HY-156202

Geranylgeranoic acid	Histone Demethylase PD-1/PD-L1 Apoptosis	Cancer
Geranylgeranoic acid (Compound 5) is inhibits lysine-specific demethylase 1 (LSD1) with an IC₅₀ value of 46.97 µM. Geranylgeranoic acid induces apoptosis via loss of the mitochondrial membrane potential and activation of interleukin-1β-converting enzyme (ICE) and cysteine protease precursor 32 (CPP32) in Huh7 and PLC/PRF/5 human hepatoma cells and MLE-10 transformed mouse hepatocytes. Geranylgeranoic acid an isoprenoid with anticancer activity, which is found in S. chinensis .

HY-70083

SPK-601 LMV-601	Phospholipase Reverse Transcriptase	Infection
SPK-601 (LMV-601) is an inhibitor of the phosphatidylcholine-specific phospholipase C (PC-PLC). SPK-601 also can be used as an antimicrobial agent .

HY-153213A

Org 274178-0	TSH Receptor	Endocrinology
Org 274178-0 is a selective thyroid-stimulating hormone receptor (TSHR) antagonist with a pIC₅₀ value for TSHR is 5.03. Org 274178-0 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by thyroid-stimulating hormone (TSH) and TSH receptor-stimulating immunoglobulins (TSIs). Org 274178-0 is promising for research of Graves’ disease and Graves’ ophthalmopathy .

HY-B0470R

Neomycin sulfate (Standard)	Reference Standards Bacterial Antibiotic Phospholipase	Infection Cancer
Neomycin (sulfate) (Standard) is the analytical standard of Neomycin (sulfate). This product is intended for research and analytical applications. Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .

HY-P2817

Phospholipase C plcs	Phospholipase	Infection Metabolic Disease
Phospholipase C (PLCs) is a class of phospholipases. Phospholipase C participates in cellular signaling and regulation by virtue of its ability to hydrolyze membrane phospholipids into di-acyl-glycerol (DAG) and inositol triphosphate (IP3), which further causes the activation of other signaling pathways involved in various processes, including immune response .

HY-176525

PLC-β-IN-1	Phospholipase	Inflammation/Immunology
PLC-β-IN-1 (Compound 8a) is a PLCβ inhibitor. PLC-β-IN-1 exerts anti-airway contraction activity by inhibiting PLCβ and its downstream signaling pathways, and can enhance the airway relaxation effect of β-agonists. PLC-β-IN-1 can be used in the study of asthma .

HY-W795960

D-myo-Inositol 1,4,5-trisphosphate sodium salt	Biochemical Assay Reagents Calcium Channel Phospholipase	Neurological Disease Metabolic Disease
D-myo-inositol 1,4,5-trisphosphate sodium salt is a widely distributed intracellular second messenger. D-myo-inositol 1,4,5-trisphosphate sodium salt acts as a potent agonist of the Ins (1,4,5) P₃ receptor with an EC₅₀ of 0.12 μM and inhibits bovine *PLC-δ1, with an IC₅₀* of 5.4 μM for binding and an IC₅₀ of 12.4 μM for hydrolysis. D-myo-inositol 1,4,5-trisphosphate sodium saltis metabolized into Ins (1,4) P₂ and Ins (1,3,4,5) P₄. D-myo-inositol 1,4,5-trisphosphate sodium salt mediates various cellular processes, including growth, development, fertilization, secretion, contraction and neuromodulation. D-myo-inositol 1,4,5-trisphosphate sodium salt inhibits PIP₂ hydrolysis and Ca ²⁺-ATPase activity. D-myo-inositol 1,4,5-trisphosphate sodium salt is used for cardiac preconditioning, exerts cardioprotective effects and mimics ischemic preconditioning. D-myo-inositol 1,4,5-trisphosphate sodium salt is applied in studies related to intracellular calcium and phosphoinositol signaling pathways .

HY-148388

N-Stearoylsphingomyelin N-Stearoyl-D-sphingomyelin	Phospholipase	Cancer
N-Stearoylsphingomyelin (N-Stearoyl-D-sphingomyelin) is a sphingolipid, which can inhibit Phospholipase Cδ1 (PLCδ1) .

HY-N15873

XY-69 triethylamine	Biochemical Assay Reagents	Others
XY-69 triethylamine is a fluorescent analog of PIP2. XY-69 liposomal assay can be utilized in monitoring PLC enzymatic activity .

HY-110119

Galloflavin potassium	Lactate Dehydrogenase Apoptosis	Others
Galloflavin potassium is a novel lactate dehydrogenase inhibitor that can be used for the research of cancer. Galloflavin inhibits aerobic glycolysis in PLC/PRF/5 cells and triggers cell death via apoptosis .

HY-155513

Syk-IN-8	Syk	Cancer
Syk-IN-8 (compound 19q) is a Syk inhibitor, with antiproliferative activity against multiple hematological tumour cells. Syk-IN-8 inhibits PLCγ2 phosphorylation, can be used for research in blood cancers .

HY-12598AR

DHPG (Standard) (RS)-3,5-DHPG (Standard)	mGluR Reference Standards	Neurological Disease
DHPG (Standard) is the analytical standard of DHPG. This product is intended for research and analytical applications. DHPG is the agonist for mGluR 1/5 (EC50 for mGluR 1 is 60 nM) that activates the phospholipase C (PLC) pathway, and leads ultimately to the activation of protein kinase C (PKC) .

HY-146672

ITK inhibitor 6	Itk	Cancer
ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC₅₀s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities .

HY-175407

18:0-20:4 PI(3,4,5)P3 sodium	Drug Derivative	Others
18:0-20:4 PI(3,4,5)P3 (sodium) is an analogue of phosphatidylinositol. Protein-binding to PtdIns-(3,4,5)-P3 is important for cytoskeletal rearrangements and membrane trafficking. PtdIns-(3,4,5)-P3 is resistant to cleavage by PI-specific PLC .

HY-175982

AURKA-IN-3	Aurora Kinase	Cancer
AURKA-IN-3 (Compound AL8) is an irreversible covalent Aurora kinase A (AURKA) inhibitor with an IC₅₀ value of 23.0 nM. AURKA-IN-3 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by AURKA, and reduces the autophosphorylation level of AURKA. AURKA-IN-3 is promising for research of malignant tumors associated with high AURKA expression (e.g., leukemia, lymphoma) .

HY-162280

PROTAC BTK Degrader-9	PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk	Cancer
PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca ²⁺-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .

HY-P10833

C-VGB3	VEGFR PI3K Akt mTOR ERK Apoptosis	Cardiovascular Disease Cancer
C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer .

HY-185206

BSJ-05-037	PROTACs Itk NF-κB	Cancer
BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines. BSJ-05-037 blocks the activation of the NF-κB/GATA-3 signaling pathway, inhibits PLCγ1 phosphorylation, and reduces the proliferative capacity of T-cell lymphoma cells. BSJ-05-037 enhances the sensitivity of T-cell lymphoma cells to chemotherapy. In mouse models of T-cell lymphoma, BSJ-05-037 induces ITK degradation, reduces GATA-3 expression, decreases tumor volume, and reverses chemotherapy resistance. BSJ-05-037 is applicable to research related to T-cell lymphoma .

HY-120406

PLS-123	Btk Akt mTOR p38 MAPK ERK CCR Apoptosis	Cancer
LPS-123 is a covalently irreversible BTK inhibitor with an IC₅₀ of < 5 nM. LPS-123 simultaneously inhibits the catalytic activity of BTK at Tyr551 and its self-activation at Tyr223. LPS-123 inhibits phosphorylation of the AKT/mTOR and MAPK signaling pathways, activation of PLCγ2, ERK1/2, p38, AKT, and mTOR, and blocks the production of CCL3 and CCL4 chemokines. LPS-123 exhibits significant anti-proliferative activity against various B-cell lymphoma cell lines and effectively induces apoptosis via a caspase-dependent pathway. LPS-123 also demonstrates significant antitumor activity in the OCI-Ly7 xenograft model. LPS-123 can be used for lymphoma research .

HY-172567

PLC thio-PIP2 trisodium	Biochemical Assay Reagents Phospholipase	Others
PLC thio-PIP2 trisodium is an analog of naturally occurring PIP2. PLC thio-PIP2 trisodium can simulate the process of PIP2 being hydrolyzed by PLC in in vitro experiments, and then quantitatively analyze the activity of PLC by detecting the free thiol produced by hydrolysis .

HY-RS19691

Hspg2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Hspg2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hspg2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hspg2 Mouse Pre-designed siRNA Set A Hspg2 Mouse Pre-designed siRNA Set A

HY-P10658

ARF1 (2-17)	Phospholipase	Others
ARF1 (2-17) inhibits both ARF-independent (PLC-β) and ARF-dependent (PLD) pathways. ARF1 (2-17) inhibits GTP-γ-S-stimulated PLD activity, phospholipase C-β (PLC-β), and exocytosis .

HY-RS06449

HSPG2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HSPG2 Human Pre-designed siRNA Set A contains three designed siRNAs for HSPG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HSPG2 Human Pre-designed siRNA Set A HSPG2 Human Pre-designed siRNA Set A

HY-P10119

PDGFR Y1021 peptide (non-phosphorylation)	PDGFR Mitosis	Others
PDGFR Y1021 peptide (non-phosphorylation) is the non-phosphorylated fragment of platelet-derived growth factor receptor (PDGFR). PDGFR Y1021 peptide (non-phosphorylation) blocks the PLCγ association to PDGFR through PLCγSH2 domain, and thus inhibits mitogenic response .

HY-P10270

PDGFR Y1021 peptide (phosphorylation)	PDGFR Mitosis	Others
PDGFR Y1021 peptide (phosphorylation) is the phosphorylated fragment of platelet-derived growth factor receptor (PDGFR). PDGFR Y1021 peptide (phosphorylation) supports association of PLCγ to PDGFR through PLCγSH2 domains, and thus promotes the production of inositol phosphates and mitogenic response .

HY-103411

SKF83822 hydrobromide	Dopamine Receptor	Neurological Disease
SKF83822 hydrobromide is a potent dopamine D1 receptor agonist. SKF83822 hydrobromide activates G_s/_olf/adenylyl cyclase (AC)-coupled D1 receptors, but not phospholipase C (PLC)-coupled D1-like receptors .

Cat. No.	Product Name	Type

HY-148123

Glycerophospholipids, cephalins

Biochemical Assay Reagents

Glycerophospholipids and cephalins are a class of phospholipid compounds and important components of neural membranes. Glycerophospholipids and cephalins are hydrolysis substrates of phospholipase (such as PLA2, PLC, and PLD). After complete hydrolysis, they produce 1 mol of glycerol, phosphate, ethanolamine, and 2 mol of fatty acids, respectively. Glycerophospholipids and cephalins can maintain membrane structure, fluidity, and ion permeability, and serve as precursors of second messengers such as arachidonic acid and diacylglycerol. Glycerophospholipids and cephalins can regulate signal transduction, cell apoptosis, and membrane transport, and are used in the study of neurodegenerative diseases (such as Alzheimer's disease) .

HY-W795960

D-myo-Inositol 1,4,5-trisphosphate sodium salt

Biochemical Assay Reagents

D-myo-inositol 1,4,5-trisphosphate sodium salt is a widely distributed intracellular second messenger. D-myo-inositol 1,4,5-trisphosphate sodium salt acts as a potent agonist of the Ins (1,4,5) P₃ receptor with an EC₅₀ of 0.12 μM and inhibits bovine PLC-δ1, with an IC₅₀ of 5.4 μM for binding and an IC₅₀ of 12.4 μM for hydrolysis. D-myo-inositol 1,4,5-trisphosphate sodium saltis metabolized into Ins (1,4) P₂ and Ins (1,3,4,5) P₄. D-myo-inositol 1,4,5-trisphosphate sodium salt mediates various cellular processes, including growth, development, fertilization, secretion, contraction and neuromodulation. D-myo-inositol 1,4,5-trisphosphate sodium salt inhibits PIP₂ hydrolysis and Ca ²⁺-ATPase activity. D-myo-inositol 1,4,5-trisphosphate sodium salt is used for cardiac preconditioning, exerts cardioprotective effects and mimics ischemic preconditioning. D-myo-inositol 1,4,5-trisphosphate sodium salt is applied in studies related to intracellular calcium and phosphoinositol signaling pathways .

Cat. No.	Product Name	Target	Research Area

HY-P2141

TRV-120027 3 Publications Verification TRV027	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .

HY-P10833

C-VGB3	VEGFR PI3K Akt mTOR ERK Apoptosis	Cardiovascular Disease Cancer
C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer .

HY-P10658

ARF1 (2-17)	Phospholipase	Others
ARF1 (2-17) inhibits both ARF-independent (PLC-β) and ARF-dependent (PLD) pathways. ARF1 (2-17) inhibits GTP-γ-S-stimulated PLD activity, phospholipase C-β (PLC-β), and exocytosis .

HY-P10119

PDGFR Y1021 peptide (non-phosphorylation)	PDGFR Mitosis	Others
PDGFR Y1021 peptide (non-phosphorylation) is the non-phosphorylated fragment of platelet-derived growth factor receptor (PDGFR). PDGFR Y1021 peptide (non-phosphorylation) blocks the PLCγ association to PDGFR through PLCγSH2 domain, and thus inhibits mitogenic response .

HY-P10270

PDGFR Y1021 peptide (phosphorylation)	PDGFR Mitosis	Others
PDGFR Y1021 peptide (phosphorylation) is the phosphorylated fragment of platelet-derived growth factor receptor (PDGFR). PDGFR Y1021 peptide (phosphorylation) supports association of PLCγ to PDGFR through PLCγSH2 domains, and thus promotes the production of inositol phosphates and mitogenic response .

HY-P1834

MARCKS Peptide(151-175), Phosphorylated	Peptides	Inflammation/Immunology
MARCKS Peptide(151-175), Phosphorylated is a phosphorylated peptide corresponding to the basic effector domain of myristoylated alanine-rich protein kinase C substrate protein (MARCKS). Phosphorylation of MARCKS Peptide (151-175) reverses its inhibition of phospholipase C (PLC)-catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991413

ZEB85	Trk Receptor ERK Akt p38 MAPK	Neurological Disease Inflammation/Immunology
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .

HY-P991964

Rendomab B4 Rendomab-B49	Endothelin Receptor	Cancer
Rendomab B4 is a monoclonal antibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research .

HY-P991744

Anti-Mouse CXCR4 Antibody (Cx4Mab-1)	CXCR	Cancer
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma .

Species:	Human (2)
Tag:	His (1) GST (1)
Source:	E. coli Cell-free (1) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702447

	SMPD2 Protein, Human (Cell-Free, His) Sphingomyelin phosphodiesterase 2; Lyso-platelet-activating factor-phospholipase C; Lyso-PAF-plc; Neutral sphingomyelinase; N-SMase; nSMase; nSMase1	Human	E. coli Cell-free
	In vitro experiments have demonstrated that the sphingomyelin phosphodiesterase 2 (SMPD2) protein plays a key role in catalyzing the hydrolysis of sphingomyelin, leading to the formation of ceramide and phosphocholine. Furthermore, SMPD2 exhibits its enzymatic activity by hydrolyzing 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (hemolytic platelet-activating factor) in vivo. SMPD2 Protein, Human (Cell-Free, His) is the recombinant human-derived SMPD2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

HY-P703036

	PLCD4 Protein, Human (sf9, GST) 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-4; hplcD4; Phosphoinositide phospholipase C-delta-4; Phospholipase C-delta-4 (plc-delta-4)	Human	Sf9 insect cells
	PLCD4 Protein, Human (sf9, GST) is the recombinant human-derived PLCD4, expressed by Sf9 insect cells , with GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (6) Rabbit (7)
Reactivity:	Human (13) Rat (5) Mouse (5) Monkey (2)
Application:	IHC-P (10) ICC/IF (10) IP (4) WB (13) FC (6) ELISA (9)
Isotype:	IgG,Kappa (1) IgG (5) IgG, Kappa (1) IgG1 (4) IgG2b (2)
Conjugation:	Non-conjugated (13)
Clonality:	Monoclonal (7) Monoclonal Antibody (2) Recombinant (5)
Modification:	Phosphorylated (1) Unmodified (8)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84153

	Phospholipase C gamma 1 Antibody (YA3850) plc1; NCKAP3; plc-II; plc148; plcgamma1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Rat, Monkey
	Phospholipase C gamma 1 Antibody (YA3850) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Phospholipase C gamma 1.

HY-P84154

	Phospholipase C gamma 1 Antibody (YA3851) plc1; NCKAP3; plc-II; plc148; plcgamma1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse
	Phospholipase C gamma 1 Antibody (YA3851) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Phospholipase C gamma 1.

HY-P84135

	PLCG2 Antibody (YA3832) FCAS3; APLAID; plc-IV; plc-gamma-2	WB, ICC/IF, FC, ELISA	Human
	PLCG2 Antibody (YA3832) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PLCG2.

HY-P84153A

	Phospholipase C gamma 1 Antibody (YA3850)(PBS only) plc1; NCKAP3; plc-II; plc148; plcgamma1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Rat, Monkey
	Phospholipase C gamma 1 Antibody (YA3850) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Phospholipase C gamma 1.

HY-P84154A

	Phospholipase C gamma 1 Antibody (YA3851)(PBS only) plc1; NCKAP3; plc-II; plc148; plcgamma1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse
	Phospholipase C gamma 1 Antibody (YA3851) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Phospholipase C gamma 1.

HY-P84135A

	PLCG2 Antibody (YA3832)(PBS only) FCAS3; APLAID; plc-IV; plc-gamma-2	WB, ICC/IF, FC, ELISA	Human
	PLCG2 Antibody (YA3832) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PLCG2.

HY-P87838

	PLC γ2 Antibody (YA7523)	WB, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	PLC γ2 Antibody (YA7523) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to PLC γ2.

HY-P80427

	Phospholipase C gamma 1 Antibody (YA179) plc gamma 1 antibody; plc II antibody; plc-148 antibody; plcgamma1 antibody; plcG1; NCKAP3	WB, ICC/IF, IP	Human
	Phospholipase C gamma 1 Antibody (YA179) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospholipase C gamma 1.

HY-P86178

	Phospholipase C gamma 1 Antibody (YA5870) plcG1; plc1; 1-phosphatidylinositol 4; 5-bisphosphate phosphodiesterase gamma-1; plc-148; Phosphoinositide phospholipase C-gamma-1; Phospholipase C-II; plc-II; Phospholipase C-gamma-1; plc-gamma-1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospholipase C gamma 1 Antibody (YA5870) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospholipase C gamma 1.

HY-P87859

	*Phospho-PLC* γ1 (Tyr783) Antibody (YA7544)**	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-PLC γ1 (Tyr783) Antibody (YA7544) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-PLC γ1 (Tyr783).

HY-P83555

	ERp57 Antibody (YA3300) ERp57; ERp60; ERp61; Glucose Regulated Protein 58 Kd; HsT17083; p58; PDIA3; Phospholipase C alpha; PI plc	WB, IHC-P, IP	Human
	ERp57 Antibody (YA3300) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ERp57.

HY-P810555

	Phospholipase C beta 3/PLCB3 Antibody (YA9824) plcB3; 1-phosphatidylinositol 4; 5-bisphosphate phosphodiesterase beta-3; Phosphoinositide phospholipase C-beta-3; Phospholipase C-beta-3; plc-beta-3	WB, IHC-P	Human
	Phospholipase C beta 3/PLCB3 Antibody (YA9824) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospholipase C beta 3/PLCB3.

HY-P82949

	Phospholipase C beta 3 Antibody (YA2694) plcB3; 1-phosphatidylinositol 4; 5-bisphosphate phosphodiesterase beta-3; Phosphoinositide phospholipase C-beta-3; Phospholipase C-beta-3; plc-beta-3	WB, IHC-P	Human
	Phospholipase C beta 3 Antibody (YA2694) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospholipase C beta 3.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

plc-

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products